Covalent inactivation of Mycobacterium thermoresistibile inosine-5'-monophosphate dehydrogenase (IMPDH). by Trapero, Ana et al.
     
 
Graphical Abstract 
To create your abstract, type over the instructions in the template box below. 




Covalent Inactivation of Mycobacterium  
thermoresistibile inosine-5´-monophosphate 
dehydrogenase (IMPDH) 
Ana Trapero, Angela Pacitto, Daniel Shiu-Hin Chan, Chris Abell, Tom L. Blundell, David B. Ascher, Anthony 
G. Coyne  
 
Leave this area blank for abstract info. 




Bioorganic & Medicinal Chemistry Letters 
journa l  homepage:  www.e lsev ier .com  
 
Covalent Inactivation of Mycobacterium thermoresistibile inosine-5´-monophosphate 
dehydrogenase (IMPDH) 
Ana Traperoa,‡, Angela Pacittob,‡, Daniel Shiu-Hin Chana, Chris Abella,  Tom L. Blundellb,*, David B. 
Ascherb,c,*, Anthony G. Coynea* 
   
aDepartment of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW, United Kingdom.  
bDepartment of Biochemistry, University of Cambridge, 80 Tennis Court Road, Cambridge CB2 1GA, United Kingdom. 
cDepartment of Biochemistry and Molecular Biology, Bio21 Institute, University of Melbourne, 30 Flemington Road, Parkville, Victoria 3052, 
Australia.                                                                                         
   *Corresponding authors at: Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW, United Kingdom (AGC).  
    E-mail addresses: david.ascher@unimelb.edu.au (DBA), tom@cryst.bioc.cam.ac.uk (TLB), agc40@cam.ac.uk (AGC). 
    ‡ These authors contributed equally. 
 
 Inosine-5´-monophosphate dehydrogenase (IMPDH, E.C. 
1.1.1.205), a crucial enzyme required for de novo synthesis of 
guanine nucleotides, is considered an important drug target 
for immunosuppressive,1 cancer,2,3 antiviral4 and 
antimicrobial chemotherapy.5 
 IMPDH is the enzyme that catalyzes the oxidation of 
inosine 5´-monophosphate (IMP) to xanthosine 5´-
monophosphate (XMP) with the concomitant reduction of the 
cofactor nicotinamide adenine dinucleotide (NAD+) to 
NADH. The reaction involves the initial attack of an active 
site cysteine 331 (numbering in human IMPDH) on the 2-
position of IMP, followed by hydride transfer from the E-
IMP intermediate to NAD+. The resulting covalent enzyme 
intermediate E-XMP* is hydrolysed to XMP, regenerating 
the free enzyme.6  
 IMPDH has been isolated from 11 different sources and 
several X-ray crystal structures of IMPDH, including the 
Mycobacterium thermoresistibile (Mth) IMPDH protein,7, 8, 9 
have recently been determined in complex with substrate, 
product and cofactors along with a number of new inhibitors. 
IMPDH is a homotetramer, with each subunit composed of  
 
 
Fig. 1. Structures of selected covalent inhibitors of IMPDH. 
 
two domains, the larger catalytic domain and a smaller 
domain containing tandem cystathione β-synthase (CBS) 
motifs.10 Deletion of the CBS domain does not impact enzymatic 
properties or tetramer formation, but it does improve 
crystallization and solubility. 
 The existing IMPDH inhibitors have been divided into 
three major groups with respect to the binding position and  






Inosine-5´-monophosphate dehydrogenase (IMPDH) is a rate-limiting enzyme involved in 
nucleotide biosynthesis. Because of its critical role in purine biosynthesis, IMPDH is a 
drug design target for immunosuppressive, anticancer, antiviral and antimicrobial 
chemotherapy. In this study, we use mass spectrometry and X-ray crystallography to show 
that the inhibitor 6-Cl-purine ribotide forms a covalent adduct with the Cys-341 residue of 
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Fig. 2. Mechanism of human IMPDH type II inactivation by 6-Cl-
purine ribotide.  
 
the competitive relationship with IMP and NAD+.11 One 
group comprises ligands that target the binding pocket of the 
natural substrate, IMP. The other group of ligands includes 
those that target the site of the cofactor, NAD+/NADH.6 
Moreover, it has been suggested that a third ligand binds to a 
putative allosteric site far from the IMP and NAD+ pockets. 
 Covalent inhibitors contain specific functional groups, 
designed to react with a corresponding site in the target, 
typically an amino acid side chain.12 Analogs of IMP have 
been designed to react with Cys-331 (numbering in human 
IMPDH) of the enzyme to form covalent bonds, including 6-
Cl-purine ribotide,13, 14 2-CH2Cl-IMP,15  2-CH2F-IMP,15 2-
vinyl-IMP,15, 16 2-F-vinyl-IMP17 and EICARMP18 (Fig. 1).  
 Covalent inhibitors have been shown to be useful in 
identifying amino acid residues that are important for 
substrate binding and catalysis.19 It is particularly interesting 
to develop an inhibitor, which is also a substrate analog as in 
the case of 6-Cl-purine ribotide, since its primary reactive site 
would be in the active site of the enzyme. 
6-Cl-purine ribotide has previously been reported to 
irreversibly inactivate IMPDH from Aerobacter aerogenes.20 
Modification of the catalytic cysteine has been verified,14 and 
an X-ray crystal structure at a 2.9 Å resolution of human 
IMPDH type II in complex with 6-Cl-purine ribotide and the 
NAD analogue selenazole-4-carboxamide adenine 
dinucleotide has previously been reported.13 The X-ray 
crystal structure of 6-Cl-purine ribotide with human IMPDH 
type II shows that the 6-chloro-substituted purine base is 
dehalogenated and forms a covalent bond at C-6 position on 
the purine ring with the thiol group of Cys-331 (Fig. 2). 
 In this paper, we report on the novel synthesis of 6-Cl-
purine ribotide and the use of mass spectrometry and X-ray 
crystallography analysis of Mth IMPDH modified by the 
covalent inhibitor 6-Cl-purine ribotide. This study shows that 
6-Cl-purine ribotide can irreversible bind to a Cys-331 
located at the IMP binding site of the enzyme offering the 
possibility to develop selective covalent inhibitors. 
A synthesis of 6-Cl-purine ribotide has been previously 
described in the literature,21, 22 however the reproducibility of 
of the reported methods proved challenging. It was decided to 
develop an alternative route to this compound. 
The covalent IMPDH inhibitor 6-Cl-purine ribotide (1) 
was synthesized from 6-chloropurine riboside according to 
the reaction sequence described in Scheme 1.  In the first 
step, the primary hydroxyl group of the 6-chloropurine 
riboside was phosphorylated using dimethylchlorophosphate 
in pyridine at room temperature to obtain the phosphate  
 
Scheme 1. Synthesis of 6-Cl-purine ribotide (1). 
 
dimethyl ester 2 in 82% yield. The next step to directly obtain 
6-Cl-purine ribotide was to remove the methyl phosphate 
protecting groups of compound 2 but attempts with TMSBr 
in MeCN failed. A likely depurination reaction took place 
during isolation of 6-Cl-purine ribotide as evidenced by 
LCMS and 1H-NMR. It was anticipated that protection of the 
3,4-diol 2 with acid resistant and electron attracting 
protecting groups should retard glycosidic bond cleavage 
during removal of the methyl phosphate protecting groups 
with TMSBr.23 Acetyl groups were chosen for protection, as 
they can be conveniently removed under mild alkaline 
conditions. Protection of the 3,4-hydroxyl groups of 2 by 
acetyl groups using acetic anhydride and pyridine gave the 
diacetate 3 in 70% yield (Scheme 1). 
 The next steps in the synthetic path from compound 3 was 
the removal of the methyl esters and acetyl groups. Removal 
of the methyl esters was carried out in a quantitative yield 
with an excess of TMSBr in MeCN to give 4, which was 
obtained by evaporation of the volatiles and was sufficiently 
pure, as evidenced by 1H-NMR and LCMS, to be used for the 
next step without purification. This showed that protection of 
the 3,4-hydroxyl functions by acetyl groups suppressed 
depurination during removal of the methyl phosphate 
protecting groups with TMSBr. 
 The final step of the synthesis requires the removal of the 
acetyl groups in compound 4. This was accomplished by 
treatment with a solution of ammonia in methanol to give the 
desired covalent inhibitor 6-Cl-purine ribotide (1) in an 
overall yield of 56% over the four steps (Scheme 1).  
 
Mth IMPDH, which shares 85% sequence identity with 
Mycobacterium tuberculosis (Mtb) IMPDH and is 100%  
identical in the active site, was chosen for the mass 
spectroscopy and structural studies because it gave higher 
protein expression yields and better diffracting crystals than 
the Mtb orthologue. The deletion of the CBS domains 
facilitated crystallization of enzymes from several other 
organisms,24 therefore a variant of Mth IMPDH with a GG 
linker replacing the two CBS domains was constructed,  
     
 
 
Fig. 3. Deconvoluted ESI-MS spectra for a) Mth IMPDH ΔCBS 
and b) Mth IMPDH ΔCBS treated with 1, showing addition of 330 
Da after addition of 1. Insets show mass spectra before 
deconvolution. 
 
this will be referred to as Mth IMPDH ΔCBS. We recently 
reported the development of potent Mth IMPDH ΔCBS 
inhibitors using fragment-based screening and structure-
based design techniques.7 
Mass spectroscopy is an excellent technique to confirm the 
formation of a covalent enzyme-inhibitor adduct.25 The 
verification of the covalent nature of the interaction between Mth 
IMPDH ΔCBS and 1, was examined using electrospray 
ionization-mass spectrometry (ESI-MS) under denaturating 
conditions (Fig. 3). 
 In the absence of 1, Mth IMPDH ΔCBS displayed a m/z 
signal at 39813 Da (Fig. 3a), consistent with the expected 
mass of the construct (39812 Da). The treatment of Mth 
IMPDH ΔCBS with an excess of the covalent inhibitor 1 
caused a 330 Da shift in the m/z signal to 40143 Da (Fig. 3b). 
This result is consistent with the covalent attachment of 6-Cl-
purine ribotide (1) (366 Da) to the enzyme with the 
elimination of HCl (36 Da). The presence of just a single 
shifted peak indicates that the covalent modification has 
occurred on only one residue. 
 The X-ray crystal structure of Mth IMPDH ΔCBS with 
the inhibitor 6-Cl-purine ribotide (1) was solved at a 
resolution of 1.6 Å (PDB ID: 6MJY). The electron density 
showed 6-Cl-purine ribotide covalently bound in the IMP 
binding pocket of Mth IMPDH ΔCBS. In addition to the 
covalent bond to a nearby cysteine residue (C341), 6-Cl-
purine ribotide made a strong network of primarily polar and 
hydrogen bonds to the protein (Fig. 4a).  
The analysis of the binding pocket revealed a strong 
hotspot binding26 potential region that was occupied by the 6-
Cl-purine ribotide (Fig. 4b), suggesting that this site could be 
target from a drug discovery approach. A second hotspot 
binding potential region, which corresponded to the NADH 
binding site, was observed towards the entrance to the pocket.  
When the comparison of the binding orientation of 6-Cl-
purine ribotide in the Mth IMPDH ΔCBS structure to 
previous structure with human IMPDH enzyme (PDB IDs: 
1B3O,13 1JCN and 1NFB) revealed that due to differences in 
the binding pockets, 6-Cl-purine ribotide bound in a different 
orientation (Fig. 4c). This opens up potential for the 
development of novel inhibitors that can target mycobacterial 
enzymes. 
   
Fig. 4. (a) The X-ray crystal structures of Mth IMPDH ΔCBS 
(grey ribbon) with 6-Cl-purine ribotide (magenta sticks). (A) The 
interactions made by 6-Cl-purine ribotide (1) in the X-ray crystal 
structures of the complexes with Mth IMPDH ΔCBS (grey) were 
calculated by Arpeggio,27 with ring and pi interactions shown in 
green, amide–amide in blue, hydrogen bonds in red, and polar 
interactions in orange. Residue numbering is of the 
mycobacterium tuberculosis sequence. (b) The hotspot26 binding 
potential of Mth IMPDH ΔCBS Calculated hydrogen donor 
regions are coloured in blue, hydrogen acceptor regions in red and 
apolar regions in yellow. The additional binding potential towards 
to entrance to the pocket is where NADH binds. (c) Comparison 
of the binding orientation of 6-Cl-purine ribotide in Mth IMPDH 
ΔCBS to the crystal structure of human type II IMPDH (PDB ID: 
1NFB). 
 
     
 
In conclusion, this study reports on the synthesis of the 
irreversible inhibitor 6-Cl-purine ribotide and the covalent 
engagement of the Cys-341 residue of Mth IMPDH ΔCBS 
enzyme and the inhibitor. This covalent interaction was 
confirmed by mass spectrometry and X-ray crystallography 
studies. The mass spectrometry results indicated a shift of 
330 Da upon treatment of Mth IMPDH ΔCBS with an excess 
of inhibitor 6-Cl-purine ribotide, consistent with the covalent 
attachment of the inhibitor to the enzyme. In addition, an X-
ray crystal structure of 6-Cl-purine ribotide bound to Mth 
IMPDH ΔCBS showed that the 6-chloro-subtituted purine 
base was dehalogenated and forms a covalent bond at C-6 
position on the purine ring with the thiol group of Cys341 in 
a novel conformation in comparison to previous covalent 
inhibitors. The information from the X-ray crystal structure 
offers the possibility for the development of selective 
covalent inhibitors of IMPDH from mycobacteria.  
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